Athersys Stock Forecast, Price & News

Athersys (NASDAQ:ATHX) Frequently Asked Questions

Is Athersys a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athersys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHX, but not buy additional shares or sell existing shares.
View analyst ratings for Athersys or view top-rated stocks.

How has Athersys' stock price been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has decreased by 37.8% and is now trading at $0.7960.
View which stocks have been most impacted by COVID-19.

Are investors shorting Athersys?

Athersys saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 10,830,000 shares, a decrease of 34.0% from the December 15th total of 16,420,000 shares. Based on an average trading volume of 1,860,000 shares, the days-to-cover ratio is presently 5.8 days. Currently, 5.0% of the shares of the company are short sold.
View Athersys' Short Interest.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Athersys.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $4.79 million for the quarter. During the same quarter last year, the firm posted ($0.11) EPS.
View Athersys' earnings history.

What price target have analysts set for ATHX?

1 Wall Street analysts have issued 12 month price targets for Athersys' shares. Their forecasts range from $1.25 to $1.25. On average, they anticipate Athersys' share price to reach $1.25 in the next year. This suggests a possible upside of 57.0% from the stock's current price.
View analysts' price targets for Athersys or view top-rated stocks among Wall Street analysts.

Who are Athersys' key executives?

Athersys' management team includes the following people:

• William B. J. Lehmann, President, Chief Executive & Operating Officer (LinkedIn Profile)
• Ivor MacLeod, Chief Financial & Accounting Officer (LinkedIn Profile)
• John J. Harrington, Director, Chief Scientific Officer & Executive VP (LinkedIn Profile)
• Rakesh Ramachandran, Head-Information Technology & Communications
• Eric Jenkins, Senior Director-Medical & Head-Clinical Operations

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Athersys' key competitors?

Some companies that are related to Athersys include Ventyx Biosciences (VTYX), Tango Therapeutics (TNGX), Edgewise Therapeutics (EWTX), Kiniksa Pharmaceuticals (KNSA), Akero Therapeutics (AKRO), Seres Therapeutics (MCRB), Emisphere Technologies (EMIS), Praxis Precision Medicines (PRAX), Avidity Biosciences (RNA), Stoke Therapeutics (STOK), COMPASS Pathways (CMPS), Amryt Pharma (AMYT), Arcturus Therapeutics (ARCT), Cara Therapeutics (CARA) and Karyopharm Therapeutics (KPTI).
View all of ATHX's competitors.

What other stocks do shareholders of Athersys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $0.80.

How much money does Athersys make?

Athersys has a market capitalization of $187.25 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78.76 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 97 workers across the globe.

When was Athersys founded?

Athersys was founded in 1995.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

Where are Athersys' headquarters?

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at [email protected], or via fax at 216-361-9495.